Trade Resources Industry Views Product Offering Additions Will Allow GE Healthcare to Develop "End-to-End" Technologies

Product Offering Additions Will Allow GE Healthcare to Develop "End-to-End" Technologies

Ge Buys Thermo Fisher Life Sciences Technology

Cell culture and gene modulation technology, as well as magnetic beads used protein analysis and medical diagnostics, are included in GE's $1.06 billion acquisition of life science business lines from Thermo Fisher Scientific.

GE announced Monday that the product offering additions will allow GE Healthcare to develop "end-to-end" technologies for cell biology research, cell therapy, and the manufacture of innovative medicines and vaccines.

Buying Thermo Fisher's Sera-Mag magnetic beads product line enables GE to extend its existing technologies in protein analysis and medical diagnostics. The Sera-Mag beads have a high surface area per unit mass and slow settling rate with good lot-to-lot reproducibility, according to Thermo Fisher's website.

Sera-Mag Magnetic SpeedBeads, as shown on Thermo Fisher's website

Combined, the three Thermo Fisher businesses brought in about $250 million in revenue in 2013. The deal is expected to close in the first half of the year.

GE Healthcare already has a $4 billion Life Sciences business that delivers products and services for the fast-growing diagnostics, research and biopharmaceutical manufacturing sectors.

"This deal makes a good business even better and will help us realize our vision of bringing better healthcare to more people at lower cost," says John Dineen, president and CEO of GE Healthcare.

Source: http://www.qmed.com/news/ge-buys-thermo-fisher-life-sciences-technology
Contribute Copyright Policy
Ge Buys Thermo Fisher Life Sciences Technology